BTC Health Limited (ASX:BTC) is pleased to announce its investee company, BioImpact Pty Ltd, has acquired exclusive distribution rights for specialty respiratory brands Bronchitol(R) and Aridol(R) from Pharmaxis (ASX:PXS) in Australia, New Zealand, Singapore, Malaysia, Hong Kong and South Korea (Bronchitol(R) only).
BTC Health Limited (ASX:BTC) is pleased to announce the receipt of binding firm commitments for a $2.5 million private placement to fund the acquisition of exclusive distribution rights to Bronchitol(R) and Aridol(R) in Australia, New Zealand, Malaysia, Hong Kong and Singapore.
Further to Azure Health Technology Limited's (NSX:VTL) announcement on 16 March 2021 that the first manufacturing run for our finished nutraceutical products has been completed.
Azure Health Technology Limited (NSX:VTL) trading as VGI Health Technology is pleased to announce that Pitt Street Research has issued an Initiation Report.
Azure Health Technology Limited trading as VGI Health Technology (NSX:VTL) is pleased to announce that an additional current Good Manufacturing Practice (cGMP) manufacturer has been appointed in the US.
Anatara Lifesciences (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in humans and animals is pleased to provide this update on clinical trial activities.
iQX Limited (iQX Ltd) (NSX:IQX) would like to announce that Life Science Biosensor Diagnostics Pty Ltd (LSBD) in which iQX Ltd holds a 19% equity position, has received approval from the Harvard Longwood campus Institutional Review Board (IRB) to commence a clinical validation study to test patient samples from a COVID-19 repository.
